论文部分内容阅读
本文对干扰素α-2b和病毒唑联合(联合组)与单独使用干扰素α-2b(安慰剂组)治疗慢性丙型肝炎的疗效和安全性进行了随机、双盲对照研究。 病例来自瑞典5家大学医院1995年3月至6月的住院病人,符合下述情况列为研究对象:(1)转氨酶持续升高至少6个月;(2)血清抗-HCV阳性;(3)PCR法检测HCV RNA阳性;(4)治疗前12个月内肝组织学活检确诊为慢性肝炎。上述病人有下述情况者除外:曾用干扰素或病毒唑治疗;酒精成瘾或有溶
In this paper, a randomized, double-blind, controlled study of the efficacy and safety of the combination of interferon alfa-2b with ribavirin (combination group) and interferon alfa-2b alone (placebo group) in the treatment of chronic hepatitis C was performed. The cases were from inpatients from 5 University Hospitals in Sweden from March to June 1995 and were included in the study as follows: (1) Aminotransferases continued to increase for at least 6 months; (2) Serum anti-HCV was positive; (3) ) PCR detection of HCV RNA positive; (4) within 12 months before treatment of liver biopsy confirmed as chronic hepatitis. Except for those patients who had been treated with interferon or ribavirin, alcohol addiction or dissolution